Vertex Pharmaceuticals Incorporated
NASDAQ: VRTX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Reshma Kewalramani
- Employees
- 6,100
- Headquarters
- Boston, United States
- IPO year
- 1991
- Market cap
- $126.4B
- Website
- https://www.vrtx.com
Loading VRTX…
Loading profile data…Frequently asked questions about VRTX
What does Vertex Pharmaceuticals Incorporated (VRTX) do?
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations w...
Where does VRTX trade?
Vertex Pharmaceuticals Incorporated (VRTX) trades on the NASDAQ Global Select.
What sector is VRTX in?
Vertex Pharmaceuticals Incorporated (VRTX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Vertex Pharmaceuticals Incorporated?
Reshma Kewalramani is the chief executive officer of Vertex Pharmaceuticals Incorporated (VRTX).
Where is Vertex Pharmaceuticals Incorporated headquartered?
Vertex Pharmaceuticals Incorporated is headquartered in United States.
When did VRTX go public?
Vertex Pharmaceuticals Incorporated (VRTX) completed its initial public offering in 1991.